On Aug. 12, the Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for both the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines to allow for the use of an additional dose in certain immunocompromised individuals ages 12 and older. Following that announcement, the Centers for Disease Control and Prevention issued a recommendation that...
This content is restricted to members.
